Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Li, Qingguo ^a   Wang, Daorong ^a   Li, Jing ^a   Chen, Ping ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN; ERBB2 PROTEIN, HUMAN; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHINESE; COLON CARCINOMA; COLON SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CHEMISTRY; CHINA; COLON TUMOR; FOLLOW UP; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); OBSERVER VARIATION; PATHOLOGY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; CHINA; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OBSERVER VARIATION; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959561514     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-277     Document Type: Article

References (42)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogenes. Science 1987, 234:177-182.
2. Saranath D, Panchal RG, Nair R, Metha AR, Sanghavi VD, Deo MG. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Eur J Cancer 1992, 28B:139-143.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726. 10.1200/JCO.20.3.719, 11821453.
6. Caruso ML, Valentini AM. Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res 1996, 16:3813-3818.
7. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998, 55:548-555. 10.1159/000011911, 9778622.
8. Yang JL, Ow KT, Russell PJ, Ham JM, Crowe PJ. Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Ann Surg Oncol 1996, 3:574-579. 10.1007/BF02306092, 8915491.
9. Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF. Prognostic value of immunohistochemical expression of p53, HER-2/neu, and bcl-2 in stage I non-small cell lung cancer. Hum Pathol 2002, 33:105-110. 10.1053/hupa.2002.30183, 11823980.
10. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ, Landreneau RJ. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8:72-79. 10.1007/s10434-001-0072-y, 11206229.
11. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6:2803-2807.
12. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G. Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis. Clin Cancer Res 2009, 15:4680-4685. 10.1158/1078-0432.CCR-09-0192, 2742698, 19584152.
13. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. ECOG 2100: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678. 10.1200/JCO.2008.16.1612, 2653128, 18824714.
14. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, . Eastern Cooperative Oncology Group Study E3200 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 2007, 12:1539-1544. Eastern Cooperative Oncology Group Study E3200.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
16. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705. 10.1200/JCO.2005.05.112, 15738537.
17. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000, 19:3460-3469. 10.1038/sj.onc.1203685, 10918604.
18. Yen L, Benlimame N, Nie ZR, Xiao D, Wang T, Al Moustafa AE, Esumi H, Milanini J, Hynes NE, Pages G, Alaoui-Jamali MA. Differential regulation of tumor angiogenesis by distinct ErbB homo-and heterodimers. Mol Biol Cell 2002, 13:4029-44. 10.1091/mbc.E02-02-0084, 133612, 12429844.
19. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002, 94:2855-2861. 10.1002/cncr.10553, 12115372.
20. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006, 66:2028-2037. 10.1158/0008-5472.CAN-04-4559, 16489002.
21. D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G, Summerhayes IC. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989, 4:1233-1239.
22. McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, McLeod HL. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002, 86:568-573. 10.1038/sj.bjc.6600127, 2375271, 11870539.
23. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Han WK, Kim H, Ryu SH, Sepulveda AR. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007, 22:491-497. 10.1007/s00384-006-0192-8, 16947041.
24. Baiocchi G, Lopes A, Coudry RA, Rossi BM, Soares FA, Aguiar S, Guimarães GC, Ferreira FO, Nakagawa WT. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 2009, 24:1059-1068. 10.1007/s00384-009-0702-6, 19390858.
25. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW, Tobbia I. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer 2009, 9:1-6. 10.1186/1471-2407-9-1, 2648993, 19118499.
26. Demirbaş S, Sücüllü I, Yildirim S, Celenk T. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer. Turk J Gastroenterol 2006, 17:13-19.
27. Jesus EC, Matos D, Artigiani R, Waitzberg AF, Goldenberg A, Saad SS. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cir Bras 2005, 20:422-427.
28. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A. Vascular endothelial growth factor, C-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol 27:225-228.
29. Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. Her-2/neu protein expression in colorectal cancer. BMC Cancer 2006, 6:123. 10.1186/1471-2407-6-123, 1475876, 16681853.
30. Ghaffarzadegan K, Sharifi N, Vosooghynia H, Shakeri T, Ghiasi Moghadam T, Ghanad Kafi S, Lari S, Nassiri G. Her-2/neu expression in colon adenocarcinoma and its correlation with clinicopathologic variables. IJBMS 2006, 1:64-69.
31. Beckner ME. Factors promoting tumor angiogenesis. Cancer Invest 1999, 17:594-623. 10.3109/07357909909032845, 10592767.
32. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996, 15:165-76. 10.1007/BF00437469, 8842488.
33. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964-3968.
34. Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, Nishiguchi Y, Sowa M. Combined analysis of P53 and vascular endothelial growth factor expression in colorectalcarcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997, 74:502-507. 10.1002/(SICI)1097-0215(19971021)74:5<502::AID-IJC4>3.0.CO;2-7, 9355971.
35. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000, 36:748-53. 10.1016/S0959-8049(00)00003-4, 10762747.
36. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo-Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151:1523-530. 1858348, 9403702.
37. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallböhmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006, 12:29-33. 10.1158/1078-0432.CCR-05-1275, 16397020.
38. Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum 1996, 39:1073-1080. 10.1007/BF02081403, 8831518.
39. Berney CR, Yang JL, Fisher RJ, Russell PJ, Crowe PJ. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 1998, 18:973-977.
40. Do NY, Lim SC, Im TS. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck. Oncol Rep 2004, 12:229-237.
41. Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, Riggs M, Ward H, Keville L. Expression of Vascular Endothelial Growth Factor and HER2/neu in Stage II Colon Cancer and Correlation with Survival. Clin Colorectal Cancer 2004, 4:262-267. 10.3816/CCC.2004.n.025, 15555209.
42. Winlaw DS. Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant Diseases. Ann Thorac Surg 1997, 64:1204-1211. 10.1016/S0003-4975(97)00716-9, 9354565.